<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01125501</url>
  </required_header>
  <id_info>
    <org_study_id>SomaL-028 (withdrawn)</org_study_id>
    <nct_id>NCT01125501</nct_id>
  </id_info>
  <brief_title>Protandim and the Metabolic Syndrome</brief_title>
  <official_title>Protandim and the Metabolic Syndrome: A Preliminary Study to Define Protein Signatures That Change Along With Lowered Oxidative Stress Measured as F2 Isoprostanes or TBARS and Inflammation Measured as hsCRP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SomaLogic, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LifeVantage</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Protandim will decrease markers of oxidative stress/inflammation in subjects with metabolic
      syndrome and proteomics will identify protein profiles that correlate with markers or/changes
      in oxidative stress.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluate the effects of Protandim on protein profile changes and markers of inflammation and
      oxidation in subjects (40-60 years of age) with the Metabolic Syndrome.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    funding not available
  </why_stopped>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">June 2010</completion_date>
  <primary_completion_date type="Anticipated">June 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure Decrease in Oxidative Stress markers.</measure>
    <time_frame>every 30 days for 120 days</time_frame>
    <description>the primary purpose of this trial is a preliminary study to examine the relationship to markers of oxidative stress,in response to Protandim, in Metabolic Syndrome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Protein signatures</measure>
    <time_frame>every 30 days for 120 days</time_frame>
    <description>evaluating the effects of Protandim on protein profile changes in patients with metabolic syndrome</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Protandim</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>one capsule a day for 30 days of protandim given, followed by a wash out period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>one capsule a day for 30 days will be given followed by a washout period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Protandim</intervention_name>
    <description>The product Protandim used in this study have ingredients derived from five botanical sources [Bacopa monniera, Silybum marianum (milk thistle), Withania somnifera (Ashwagandha), Camellia sinensis (green tea), and Curcuma longa (turmeric)].</description>
    <arm_group_label>Protandim</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age = 40-60 years of age

          -  Meets at least 3 of the 5 criteria for the metabolic syndrome (as defined by NCEP/ATP
             III criteria)

        NCEP/ATP III criteria

          -  Central obesity as measured by waist circumference:

               -  Men — Greater than 40 inches

               -  Women — Greater than 35 inches

          -  Fasting blood triglycerides greater than or equal to 150 mg/dL

          -  Blood HDL cholesterol:

               -  Men — Less than 40 mg/dL

               -  Women — Less than 50 mg/dL

          -  Blood pressure greater than or equal to 130/85 mmHg or on anti-hypertensive Rx

          -  Fasting glucose greater than or equal to 100 but &lt; 125 mg/dL

        Exclusion Criteria:

          -  Women taking hormone replacement therapy for post menopause

          -  Signs or symptoms of acute coronary syndrome

          -  History of congestive heart failure (prior myocardial infarction, coronary artery
             disease including stent placement, coronary artery bypass graft, EBCT calcium score of
             at least 100, or a positive stress test)

          -  Serum creatinine &gt; 1.5 mg/dL, AST or ALT &gt; 2 times ULN, HgA1c &gt;6.5%, severely
             depressed or elevated blood cell lines, triglycerides &gt; 500, TSH outside of normal
             range, elevated calcium, blood pressure &gt; 160/100, urine protein &gt; 30 ,g/dl.

          -  Concurrent medical conditions/illnesses in which expected life expectancy is 2 years
             or less and/or are likely to require frequent hospitalizations and treatment
             adjustments (e.g., cirrhosis, active malignancy, , or highly active rheumatologic
             condition, lupus, rheumatoid arthritis or chronic obstructive pulmonary disease and
             diabetes).

          -  Participation in any other investigational substance or medical device study within 30
             days before this trial and/or participation in such entity during this trial.

          -  Known pregnancy.

          -  Supplementation with nutraceuticals or if so one month washout before initiating the
             study before initiating this trial.

          -  Taking statins or fibrates to lower cholesterol

          -  Inability or unwillingness to provide written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert H Eckel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2010</study_first_submitted>
  <study_first_submitted_qc>May 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2010</study_first_posted>
  <last_update_submitted>October 16, 2017</last_update_submitted>
  <last_update_submitted_qc>October 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2017</last_update_posted>
  <responsible_party>
    <name_title>Robert H. Eckel, MD; Professor of Medicine</name_title>
    <organization>Univeristy of Colorado Denver</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

